Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617146 | 0.91 | SLC6A9 (0.41) | GALR3SLC6A9ALDH1A1SMN1; SMN2HSD11B1 | |
| SCHEMBL603594 | 0.90 | SLC6A9 (0.43) | SLC6A9SMN1; SMN2CYP19A1LMNANAMPT | |
| SCHEMBL606959 | 0.88 | SLC6A9 (0.39) | GALR3SLC6A9ALDH1A1SMN1; SMN2HSD11B1 | |
| SCHEMBL603736 | 0.88 | SLC6A9 (0.52) | SLC6A9ALDH1A1 | |
| SCHEMBL604595 | 0.88 | SLC6A9 (0.45) | SLC6A9HSD11B1CYP19A1NAMPTCARM1 | |
| SCHEMBL616498 | 0.87 | SLC6A9 (0.41) | GALR3SLC6A9ALDH1A1SMN1; SMN2HSD11B1 | |
| SCHEMBL606414 | 0.87 | SLC6A9 (0.51) | GALR3SLC6A9ALDH1A1SMN1; SMN2HSD11B1 | |
| SCHEMBL603062 | 0.86 | SLC6A9 (0.58) | SLC6A9 | |
| SCHEMBL606708 | 0.85 | SLC6A9 (0.58) | GALR3SLC6A9ALDH1A1LMNA | |
| SCHEMBL617222 | 0.83 | SLC6A9 (0.43) | GALR3SLC6A9ALDH1A1SMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227930-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2016-01-05 | — | — | US | claimed |
| US-20140309206-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES | 2014-10-16 | — | — | US | claimed |
| US-8846743-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-09-30 | — | — | US | claimed |
| EP-2603481-B1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO KG (DE) | 2014-09-17 | — | — | EP | claimed |
| CN-103189337-A | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE GMBH & CO KG | 2013-07-03 | — | — | CN | claimed |
| EP-2603481-A2 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2013-06-19 | — | — | EP | claimed |
| WO-2012020131-A2 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | claimed |
| US-20120040948-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | claimed |
| US-9227930-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227930-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227930-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140309206-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES | 2014-10-16 | — | — | US | disclosed |
| US-20140309206-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES | 2014-10-16 | — | — | US | disclosed |
| US-20140309206-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES | 2014-10-16 | — | — | US | disclosed |
| EP-2603481-B1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO KG (DE) | 2014-09-17 | — | — | EP | disclosed |
| EP-2603481-B1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO KG (DE) | 2014-09-17 | — | — | EP | disclosed |
| WO-2012020131-A2 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040948-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040948-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040948-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309206-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, BCAT1, GFPT1 | GALR3 1255/4885SLC6A9 37/4885ALDH1A1 1243/4885 |
| US-20120040948-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, BCAT1, GFPT1 | GALR3 1255/4885SLC6A9 37/4885ALDH1A1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.